Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2017 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (253)	10/7/2017 1:13:10 AM
From: BulbaMan	Read Replies (1) \| Respond to of 344

10/6/2017 Contest update The week began with the horror in Las Vegas, but stocks (excluding the gun companies) seemed oblivious to the tragedy. Let’s hope next week is more peaceful. At Friday’s close, the Contest median was up 45.54% YTD (vs. up 43.58% a week ago), the Nasdaq Biotech Index (NBI) was up 28.48% YTD (vs. up 25.98% a week ago) and the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI), was up 49.24% YTD (vs. up 46.32% a week ago). The Nasdaq Composite Index (NCI) closed up 22.42% YTD (vs. up 20.67% a week ago). IMAN’s portfolio, up a smashing123.24% YTD, remained our Contest leader. Only a bit less remarkable are SMALLB’s portfolio, up 106.08% YTD and HRS’s portfolio, up 105.31% YTD in second and third place. At Friday's close, 46 of the 48 Contest portfolios were still in the green, with 33 beating the NBI and 21 continuing to beat the SPSIBI. The 195 Contest portfolio stock picks have an exceptional average YTD gain of 37.54% and a median YTD gain of 15.25%, with 122 of the 195 picks still up for the year. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.) Portfolio adjustments: 1) Forgot to note the 1:5 ORPN reverse split in last week’s update. But it was reflected in the data tables. 2) ALR buyout by Abbot at $51. ALR only held in DEWDIL’s portfolio and I reallocated proceeds. 3) KITE buyout by Gilead at $180. KITE held in two portfolios, BAGEL & TUCK, and I reallocated proceeds. 4) ALQA did a 1:10 reverse split. (All corrections, especially adjustments for splits, greatly appreciated.) Have a safe & relaxing Indigenous Peoples' Day weekend biotechies! Peace & good health, Bulba 10/6/17 Rank Name Profit/Loss 1 IMAN 123,238 2 SMALLB 106,084 3 HRS 105,305 4 KMASTR 92,994 5 ROBO 92,153 6 SCARAM 89,366 7 TOMP 86,482 8 BIOMAV 83,865 9 TUCK 81,786 10 AJM 80,648 Week's Top 5 Gainers Symbol 9/29/17 10/6/17 Wk.%chg. ITEK 1.78 2.62 47.19% ABIO 1.10 1.50 36.36% ABLX.BR 12.32 16.08 30.52% PTN 0.66 0.86 29.11% ATNM 0.58 0.72 25.20% Week's Worst 5 Losers Symbol 9/29/17 10/6/17 Wk.%chg. MNTA 18.50 12.95 -30.00% MCRB 16.04 11.92 -25.69% ALQA 3.651 2.900 -20.57% BTI.V 1.10 0.90 -18.18% RDHL 10.81 9.58 -11.38%